What is the 13F Pro Quality Score for JSPR?

13F Pro ranks Jasper Therapeutics, Inc. (JSPR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View JSPR's current score at https://13fpro.ai/research/JSPR (free sign-up required for the full ranking).

Where does 13F Pro source JSPR data?

All Jasper Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Jasper Therapeutics, Inc. files with the SEC under CIK 1788028. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is JSPR in?

Jasper Therapeutics, Inc. (JSPR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is JSPR research updated on 13F Pro?

JSPR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Jasper Therapeutics, Inc.(JSPR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1788028 JSPR stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

JSPR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Jasper Therapeutics, Inc. (JSPR), a Healthcare sector company. JSPR is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Jasper Therapeutics, Inc. reports net income of $-1.2M, free cash flow of $-14.5M. Top institutional holders of JSPR by reported 13-F value include Velan Capital Investment Management, MILLENNIUM MANAGEMENT, ACORN CAPITAL ADVISORS,, based on the most recent SEC filings. JSPR trades on the Nasdaq exchange and files with the SEC under CIK 1788028. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate JSPR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Jasper Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-1.2M

Free Cash Flow

Q1 2026

$-14.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-6.4% YoY

$-75.8MFY 2025

FY21 $-30.6MFY22 $-37.7MFY24 $-71.3MFY25 $-75.8M

Operating Income

-10.0% YoY

$-83.9MFY 2025

FY21 $-36.8MFY22 $-51.2MFY24 $-76.2MFY25 $-83.9M

EPS (Diluted)

+19.2% YoY

$-3.95FY 2025

FY21 $-2.69FY22 $-10.33FY24 $-4.89FY25 $-3.95

Total Assets

-55.2% YoY

$35.8MFY 2025

FY21 $93.7MFY22 $48.4MFY24 $79.9MFY25 $35.8M

Op. Cash Flow

-23.3% YoY

$-77.2MFY 2025

FY21 $-33.7MFY22 $-45.9MFY24 $-62.6MFY25 $-77.2M

Metric	FY 2025	FY 2024	FY 2022	FY 2021
Net Income	$-75.8M -6.4%	$-71.3M -89.1%	$-37.7M -23.0%	$-30.6M
Operating Income	$-83.9M -10.0%	$-76.2M -48.9%	$-51.2M -39.0%	$-36.8M
EPS (Diluted)	$-3.95 +19.2%	$-4.89 +52.7%	$-10.33 -284.0%	$-2.69
Total Assets	$35.8M -55.2%	$79.9M +65.2%	$48.4M -48.4%	$93.7M
Operating Cash Flow	$-77.2M -23.3%	$-62.6M -36.5%	$-45.9M -36.2%	$-33.7M

AI Insight: JSPR Financial Trends

Jasper is burning through equity at accelerating pace with no revenue, leaving ~$3M in shareholder value as of Q1 2026.

• Net losses narrowed from $24M in Q4 2024 to $1M in Q1 2026, signaling potential approach to breakeven.

• Equity collapsed 97% from $100M in Q2 2024 to $3M in Q1 2026 as cash burn continues unabated.

• Operating cash outflow remains severe: $15M–$23M per quarter with no offsetting revenue generation.

⚠ Equity base now critically low at $3M; minimal runway absent immediate fundraise or revenue inflection.

⚠ Operating losses remain $11M–$16M quarterly despite shrinking net losses—suggests one-time gains masking operational drag.

AI Insight: JSPR Ratio Trends

Jasper Therapeutics shows severe and persistent negative returns across all profitability metrics, with ROA improving to -22.2% in Q1 2026 but ROE deteriorating sharply to -138.1%.

• ROA improved from -75.0% in Q3 2024 to -22.2% in Q1 2026, suggesting reduced operating losses relative to assets.

• ROE collapsed to -138.1% in Q1 2026 from -89.1% in Q3 2024, indicating shareholder equity erosion accelerated.

⚠ Company remains deeply unprofitable across all measurement periods shown; no path to positive returns visible in data.

⚠ Sparse margin and leverage data limits assessment of burn rate and capital structure sustainability.

Get alerted when JSPR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Jasper Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of JSPR

Velan Capital Investment Management LP
$2.3M2,668,395 sh
MILLENNIUM MANAGEMENT LLC
$1.4M1,617,531 sh
ACORN CAPITAL ADVISORS, LLC
$1.2M1,411,492 sh
KINGDON CAPITAL MANAGEMENT, L.L.C.
$1.2M1,352,106 sh
MORGAN STANLEY
$1.2M1,333,420 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.0M1,172,597 sh
Rock Springs Capital Management LP
$964.5K1,100,726 sh
Carlyle Group Inc.
$934.2K1,066,189 sh
BOOTHBAY FUND MANAGEMENT, LLC
$510.6K582,751 sh
Lion Point Capital, LP
$407.4K465,000 sh

Fund	Value	Shares
Velan Capital Investment Management LP	$2.3M	2,668,395
MILLENNIUM MANAGEMENT LLC	$1.4M	1,617,531
ACORN CAPITAL ADVISORS, LLC	$1.2M	1,411,492
KINGDON CAPITAL MANAGEMENT, L.L.C.	$1.2M	1,352,106
MORGAN STANLEY	$1.2M	1,333,420
VANGUARD CAPITAL MANAGEMENT LLC	$1.0M	1,172,597
Rock Springs Capital Management LP	$964.5K	1,100,726
Carlyle Group Inc.	$934.2K	1,066,189
BOOTHBAY FUND MANAGEMENT, LLC	$510.6K	582,751
Lion Point Capital, LP	$407.4K	465,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put JSPR on your watchlist

Track score changes the day Jasper Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is JSPR a good stock to buy?

13F Pro's AI-powered analysis of Jasper Therapeutics, Inc. (JSPR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for JSPR are available on the JSPR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own JSPR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling JSPR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Jasper Therapeutics, Inc.'s investment landscape.